Bioproduction cell line engineering services

Developing biotherapeutics?

Partner with Horizon for custom editing of bioproduction cell lines to meet your specific manufacturing needs for protein and viral vector therapeutics.

Over 10 years expertise in gene editing

Horizon has a proven track record in the use of engineered cell lines for biotherapeutic manufacturing, with >60 global regulatory filings to date in multiple territories including US, EU, China, Australia and more.

Our dedicated bioproduction cell line engineering team uses a state-of-the-art CRISPR-based platform to deliver your cell line editing requirements with high precision and speed.

Built-in flexibility

Editing services are available in established Horizon cell lines (CHOSOURCE™ expression platform) or any other cell hosts provided by customers. Simply choose your cells and the type of genome editing required and we will take care of the rest.

CHO, HEK293 cells and more
Knock-in gene editing – Introduce new genes or landing pads
Knock-out gene editing – Knock out multiple genes

Functional validation of engineered cell lines is available upon request.

Trusted, trackable data

Receive fully documented history for all commercial cell lines, compliant with regulatory guidelines for IND/CTA filings.

First Name *

Last Name *

Email *

Company / Institution Optional

Country *

Zipcode or Postal Code * Optional

Describe your project goal and/or difficulties your are experiencing Optional

By providing my personal data and clicking this button, I acknowledge that Revvity, Inc. and its affiliates (“Company”) will process my personal data provided above consistent with the Company’s Privacy Policy (available here).*

I would like to stay up-to-date about offers, products and services Optional

Bioproduction cell line engineering service workflow

Additional Resources

CHOSOURCE expression platform brochure

Learn more about how the CHOSOURCE expression platform can improve your biomanufacturing performance.

View CHOSOURCE brochure

Reprogramming CHO by gene editing

Read about how CHO cell editing is revolutionizing biotherapeutic manufacturing.

View article

Harnessing cell line engineering capabilities to enhance biotherapeutic products

Read about the potential of next-generation genome editing tools for driving the success of monoclonal antibodies as biotherapeutics and the considerations to take for designing more potent therapeutic antibodies.

View paper

Leveraging next-generation cell line development technologies for cost-effective biotherapeutic applications

Read how cell line development challenges can be addressed with advanced technologies covering how to prevent clone instability, achieve acceptable protein expression, and allow for non-fragmented, multi-copy gene cassette integration.

Read paper